Resmed at SLEEP 2026: Advancing Sleep Health Through Innovation in Screening, Diagnosis and Personalized Care

Research underscores the expanding role of sleep health in whole-person care

SAN DIEGO, June 11, 2026 - Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it will present new research at SLEEP 2026, the annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17 in Baltimore, Maryland.

Resmed will present 13 research abstracts exploring the future of sleep health and highlighting new data on obstructive sleep apnea (OSA) screening, diagnosis and personalized care.

Research on a new smartphone-based approach to OSA screening, treatment patterns following the expansion of GLP-1 therapies for OSA, sleep apnea screening in women, the growing role of consumer wearables in sleep monitoring, and the impact of positive airway pressure (PAP) therapy on cardiovascular-related healthcare utilization will be showcased at the event.

SLEEP Research

13 Resmed-supported studies will be presented at SLEEP 2026. The research includes:

• Smartphone-Based Screening Shows Promise for OSA Detection

• Study Title: Smartphone Multimodal Screening for Obstructive Sleep Apnea

• Presented by: Liam Holley

• June 15, 11:00-11:45 a.m. ET

• PAP Therapy Remained the Most Common First-Line Treatment Following First Year GLP-1 Label Expansion

• Study Title: PAP Therapy and GLP-1 Use Before and After Medication Label Expansion to Treat OSA

• Presented by: Kimberly L. Sterling, PharmD, MS

• June 16, 2026, 10:00 - 10:45 a.m. ET

• Menopause and BMI Identified as Key Predictors of OSA Risk in Women

• Study Title: Informing the design of a female specific OSA screening questionnaire through symptoms and AHI-ODI
  comparative modelling

• Presented by: Shuying Yu, PhD

• June 16, 2026, 10:00 - 10:45 a.m. ET

• More than Half of People with a Chronic Sleep Disorder Use Wearables to Track Sleep

• Study Title: Associations Between Consumer Wearables and Sleep Quality in OSA, Insomnia, and COMISA

• Presented by: Leanne Kaye, PhD, MPH

• June 16, 11:00-11:45 a.m. ET

• PAP Therapy Associated With 23% Lower Risk of Cardiovascular-Related ER Visits or Hospitalizations in People with OSA and Hypertension

• Study Title: Effect of positive airway pressure therapy on healthcare resource utilization in patients with comorbid obstructive sleep apnea and hypertension

• Presented by: Kimberly L. Sterling, PharmD, MS

• June 17, 2026, 11:00 - 11:45 a.m. ET
  

Industry Product Theater:

Consumer Wearable Technologies as a Clinical Megatrend
Monday, June 15, 2026 | 11:45 a.m.-12:45 p.m. ET

Resmed Chief Medical Officer Dr. Carlos M. Nunez and ŌURA Chief Medical Officer Dr. Ricky Bloomfield will discuss how consumer wearable and sleep screening technologies are reshaping the patient journey, including earlier identification of OSA and the evolving role of physician-led diagnostic workflows.

Resmed's Innovative Diagnostic Suite at Booth #519:

Attendees are invited to visit Booth #519 to explore Resmed's portfolio of diagnostic and treatment solutions designed to help more people identify, start and stay on therapy for sleep apnea. Featured technologies include Somnoware™, myAir ™ and EasyCare Tx 2 sleep lab solution.